Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients—Review and Perspectives

por Bekes, Inga, Huober, Jens
Publicado 2023

New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development

por Koster, Kira-Lee, Huober, Jens, Joerger, Markus
Publicado 2022

Are Circulating Tumor Cells (CTCs) Ready for Clinical Use in Breast Cancer? An Overview of Completed and Ongoing Trials Using CTCs for Clinical Treatment Decisions

por Schochter, Fabienne, Friedl, Thomas W. P., deGregorio, Amelie, Krause, Sabrina, Huober, Jens, Rack, Brigitte, Janni, Wolfgang
Publicado 2019

Enhancing coping skills through brief interventions during cancer therapy – a quasi-experimental clinical pilot study

por Gelse, Norbert, Bodschwinna, Daniela, Jarczok, Marc N., Wanner, Magdalena, Volz, Madeleine, Mayer-Steinacker, Regine, Huober, Jens, Gündel, Harald, Hönig, Klaus
Publicado 2023

A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer

por Huober, Jens, Fett, Werner, Nusch, Arnd, Neise, Michael, Schmidt, Marcus, Wischnik, Arthur, Gerhardt, Steffen, Goehler, Thomas, Lück, Hans-Joachim, Rost, Andreas
Publicado 2010

Axillary Surgery in Breast Cancer Patients Treated with Breast-Conserving Surgery at German Breast Cancer Centers Within the Last 14 Years – Comparison of a University Center and a...

por de Gregorio, Amelie, Widschwendter, Peter, Albrecht, Susanne, de Gregorio, Nikolaus, Friedl, Thomas W. P., Huober, Jens, Janni, Wolfgang, Ebner, Florian K.
Publicado 2018

Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Ana...

por Rugo, Hope S., Huober, Jens, García‐Sáenz, José A., Masuda, Norikazu, Sohn, Joo Hyuk, Andre, Valerie A.M., Barriga, Susana, Cox, Joanne, Goetz, Matthew
Publicado 2020

Beneficial Molecular Adaptations in BRCA-Mutation Carriers by Combined HIT/HIRT Intervention: Results from a Pilot Study

por Bizjak, Daniel A., Schulz, Sebastian V. W., Schumann, Uwe, Otto, Stephanie, Kirsten, Johannes, Ebner, Florian, Leinert, Elena, Huober, Jens, Janni, Wolfgang, Steinacker, Jürgen Michael
Publicado 2020

nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HE...

por Hamilton, Erika, Cortes, Javier, Ozyilkan, Ozgur, Chen, Shin-Cheh, Petrakova, Katarina, Manikhas, Aleksey, Jerusalem, Guy, Hegg, Roberto, Huober, Jens, Zhang, Wei, Chen, Yanyun, Martin, Miguel
Publicado 2022

Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

por Johnston, Stephen, O’Shaughnessy, Joyce, Martin, Miguel, Huober, Jens, Toi, Masakazu, Sohn, Joohyuk, André, Valérie A. M., Martin, Holly R., Hardebeck, Molly C., Goetz, Matthew P.
Publicado 2021

Health‐Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer

por Goetz, Matthew P., Martin, Miguel, Tokunaga, Eriko, Park, In Hae, Huober, Jens, Toi, Masakazu, Stoffregen, Clemens, Shekarriz, Sarah, Andre, Valerie, Gainford, M. Corona, Price, Gregory L., Johnston, Stephen
Publicado 2020

Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial

por Banys, Malgorzata, Solomayer, Erich-Franz, Gebauer, Gerhard, Janni, Wolfgang, Krawczyk, Natalia, Lueck, Hans-Joachim, Becker, Sven, Huober, Jens, Kraemer, Bernhard, Wackwitz, Birgit, Hirnle, Peter, Wallwiener, Diethelm, Fehm, Tanja
Publicado 2013

Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma – What is the Role of Liquid Biopsy in Breast Cancer?

por Polasik, Arkadius, Tzschaschel, Marie, Schochter, Fabienne, de Gregorio, Amelie, Friedl, Thomas W. P., Rack, Brigitte, Hartkopf, Andreas, Fasching, Peter A., Schneeweiss, Andreas, Müller, Volkmar, Huober, Jens, Janni, Wolfgang, Fehm, Tanja
Publicado 2017

Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial

por Moebus, Volker, Jackisch, Christian, Schneeweiss, Andreas, Huober, Jens, Lueck, Hans-Joachim, du Bois, Andreas, Thomssen, Christoph, Kurbacher, Christian, Kuhn, Walther, Nitz, Ulrike, Runnebaum, Ingo B., Hinke, Axel, Kreienberg, Rolf, Untch, Michael
Publicado 2013

Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial

por Witzel, Isabell, Loibl, Sibylle, Wirtz, Ralph, Fasching, Peter A., Denkert, Carsten, Weber, Karsten, Lück, Hans-Joachim, Huober, Jens, Karn, Thomas, Mackelenbergh, Marion von, Marmé, Frederik, Schem, Christian, Stickeler, Elmar, Untch, Michael, Müller, Volkmar
Publicado 2019

Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial

por Di Cosimo, Serena, Porcu, Luca, Agbor-tarh, Dominique, Cinieri, Saverio, Franzoi, Maria Alice, De Santis, Maria Carmen, Saura, Cristina, Huober, Jens, Fumagalli, Debora, Izquierdo, Miguel, Piccart, Martine, Daidone, Maria Grazia, de Azambuja, Evandro
Publicado 2020

Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Prima...

por Huober, Jens, Barrios, Carlos H., Niikura, Naoki, Jarząb, Michał, Chang, Yuan-Ching, Huggins-Puhalla, Shannon L., Pedrini, José, Zhukova, Lyudmila, Graupner, Vilma, Eiger, Daniel, Henschel, Volkmar, Gochitashvili, Nino, Lambertini, Chiara, Restuccia, Eleonora, Zhang, Hong
Publicado 2022

An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)

por Risi, Emanuela, Biagioni, Chiara, Benelli, Matteo, Migliaccio, Ilenia, McCartney, Amelia, Bonechi, Martina, Guarducci, Cristina, Hilbers, Florentine, Di Cosimo, Serena, Huober, Jens, Romagnoli, Dario, Boccalini, Giulia, Vitale, Stefania, Sotiriou, Christos, Biganzoli, Laura, Di Leo, Angelo, Malorni, Luca
Publicado 2019

A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor–Positive Breast Cancer

por Jhaveri, Komal, Juric, Dejan, Yap, Yoon-Sim, Cresta, Sara, Layman, Rachel M., Duhoux, Francois P., Terret, Catherine, Takahashi, Shunji, Huober, Jens, Kundamal, Nicole, Sheng, Qing, Balbin, Alejandro, Ji, Yan, He, Wei, Crystal, Adam, De Vita, Serena, Curigliano, Giuseppe
Publicado 2021

End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO

por Di Cosimo, Serena, Ciniselli, Chiara M., Pizzamiglio, Sara, Cappelletti, Vera, Silvestri, Marco, El-Abed, Sarra, Izquierdo, Miguel, Bajji, Mohammed, Nuciforo, Paolo, Huober, Jens, Cameron, David, Chia, Stephen, Gomez, Henry L., Iorio, Marilena V., Vingiani, Andrea, Pruneri, Giancarlo, Verderio, Paolo
Publicado 2023